APR-246

The 2020 highlights in MDS 4:47
The 2020 highlights in MDS
Thomas Cluzeau
MDS: state of the art in Europe 4:10
MDS: state of the art in Europe
Valeria Santini
Advances and challenges in AML treatment 8:08
Advances and challenges in AML treatment
Naval Daver
APR-246 in TP53 mutated MDS and AML 3:00
APR-246 in TP53 mutated MDS and AML
David Sallman
The role of venetoclax in older patients with AML 5:31
The role of venetoclax in older patients with AML
Andrew Wei
APR-246 with azacitidine for p53 mutated MDS and AML 3:14
APR-246 with azacitidine for p53 mutated MDS and AML
Thomas Cluzeau
Immuno-oncology paving the way in MDS 1:53
Immuno-oncology paving the way in MDS
Uma Borate
Azacitidine in the treatment of MDS 0:52
Azacitidine in the treatment of MDS
David Steensma
Novel drug targets for MDS 1:32
Novel drug targets for MDS
Stephen Nimer
APR-246 and azacitidine in TP53m MDS and AML 1:38
APR-246 and azacitidine in TP53m MDS and AML
Thomas Cluzeau
Mutant p53 re-activator APR-246 in MDS/AML 3:03
Mutant p53 re-activator APR-246 in MDS/AML
David Sallman
MDS updates from ASH 2019 1:22
MDS updates from ASH 2019
David Steensma
What’s to come for MDS therapy? 1:45
What’s to come for MDS therapy?
David Sallman
Targeting BCL-2 in older AML: novel venetoclax combinations 3:33
Targeting BCL-2 in older AML: novel venetoclax combinations
Andrew Wei
Data for APR-246 and azacitidine in patients with mTP53 MDS and AML 3:24
Data for APR-246 and azacitidine in patients with mTP53 MDS and AML
David Sallman
Promising approaches and clinical trials in MDS 1:56
Promising approaches and clinical trials in MDS
David Steensma
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals